Coherus Oncology (CHRS) Non-Current Assets (2013 - 2026)

Coherus Oncology has disclosed Non-Current Assets across 14 years of filings, most recently posting $57.4 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 3.15% year-over-year to $57.4 million; the TTM figure through Jun 2026 stood at $224.6 million (down 38.14% YoY), while the FY2025 annual figure was $51.6 million, down 51.72% from the prior year.
• Non-Current Assets came in at $57.4 million for Q2 2026 at Coherus Oncology, down from $60.0 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $154.0 million in Q4 2023 to a low of $51.6 million in Q4 2025.
• Average Non-Current Assets over 5 years is $93.7 million, with a median of $92.9 million recorded in 2022.
• Year-over-year, Non-Current Assets jumped 57.3% in 2024 and plunged 59.14% in 2025.
• Over 5 years, Non-Current Assets stood at $99.6 million in 2022, then jumped by 54.57% to $154.0 million in 2023, then plunged by 30.54% to $107.0 million in 2024, then plunged by 51.72% to $51.6 million in 2025, then gained by 11.15% to $57.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $57.4 million in Q2 2026, $60.0 million in Q1 2026, and $51.6 million in Q4 2025.